期刊文献+

对氧磷酶长循环脂质体的制备及评价 被引量:5

Preparation and Evaluation of Long-circulating Liposomes of Paraoxonase
下载PDF
导出
摘要 目的研制对氧磷酶长循环脂质体。方法采用薄膜分散法制备对氧磷酶长循环脂质体,采用凝胶柱法测定包封率,以包封率为指标,分别考察药脂比、胆固醇用量、聚乙二醇-胆固醇用量、离子强度等对脂质体的影响,在此基础上用正交设计对处方进行优化。结果经薄膜分散法制得的脂质体包封率为(87.66±3.46)%,平均粒径为126nm左右,粒度分布均匀,呈单峰分布,电镜结果显示外形圆整,分散性较好。4℃放置15d包封率无明显变化,酶活性基本稳定。结论聚乙二醇修饰的对氧磷酶长循环脂质体制备工艺简单可行,对氧磷酶长循环脂质体制剂学、酶学性质稳定。 Objective To prepare the long-circulating hposomes of paraoxonase (PON). Methods The long-circulating liposomes of pamoxonase were prepared by film dispersion method. The encapsulation efficiency was determined by gel column. The effects of the factors on the encapsulation efficiency, such as the weight ratio of paraoxonase to phospholipid, cholesterol (Chol) to phospholipid, PEG-cholesterol (PEG-Chol) and the iron strength of water phase, were investigated respectively. Then the formulation was optimized by otthogonal design. Results The encapsulation efficiency of the paraoxonase lipesomes was 87.66_+3.46 % ,and the average diameter of the liposomes was about 126 nm. There was no significant change on encapsulation efficiency on 15 d at 4℃ ,and the activity of paraoxonase was maintained basically stable. Conclusion The preparation of PEG-modified pamoxonase liposomes was easy and practicable, and the property investigation in vitro showed that the paraoxonase lipesomes were stable.
出处 《中国医科大学学报》 CAS CSCD 北大核心 2010年第2期87-91,共5页 Journal of China Medical University
基金 国家自然科学基金资助项目(30671778) 辽宁省教育厅高校科研基金资助项目(05L480)
关键词 对氧磷酶 长循环脂质体 薄膜分散法 蛋白 粒度分布 paraoxonase long-circulating liposome film dispersion method protein partical size distribution
  • 相关文献

参考文献10

  • 1赵敏,崔玥,袁丽.兔血清中对氧磷酶的提取和纯化[J].中国医科大学学报,2009,38(7):490-492. 被引量:6
  • 2Rochu D,Chabriere E, Masson P. Human paraoxonase:A promising approach for pre-treatment and therapy of organophosphorus poisoning[ J ]. Toxicology, 2007,233 ( 1-3 ) : 47-59.
  • 3Rosenblat M,Karry R,Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum:relevance to diabetes [J].Atherosclerosis, 2006,187 ( 1 ) : 74-81.
  • 4Costa LG,Cole TB,Jarvik GP,et al. Functional genomics of the paraoxonase (PON 1 ) polymorphisms: Effects on pesticide sensitivity, cardiovasculardisease,anddrug metabolism [J].AnnuRevMed,2003,54: 371-392.
  • 5Costa LG, McDonald BE, Murphy SD, et al. Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats [J]. Toxicol Appl Pharmacol, 1990,103( 1 ) : 66-76.
  • 6Li WF, Furlong CE,Costa LG. Paraoxonase protects against chlorpyrifos toxicity in mice[J]. Toxicol Lett, 1995,76(3 ):219-226.
  • 7Kuo CL,La Du BN. Comparison of purified human and rabbit serum paraoxonases[ J]. Drug Metah Dispos, 1995,23(9) :935-944.
  • 8Eckerson HW, Romson J,Wyte C,et al. The human serum paraoxonase polymorphism:identification of phenotypes by their response to salts [J]. Am J Hum Genet, 1983,35(2) : 214-227.
  • 9Chambers JE. PON1 multitasks to protect health [J]. Proc Natl Acad Sci USA,2008,105(35): 12639-12640.
  • 10Stevens RC, Suzuki SM, Cole TB, et al. Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning [J]. Proc Natl Acad Sci USA, 2008,105(35 ) : 12780-12784.

二级参考文献12

  • 1赵赞梅,王汉斌.对氧磷酶的某些研究进展[J].毒理学杂志,2005,19(1):64-66. 被引量:10
  • 2马宏伟,赵卫国,潘柏申.亲和层析法分离纯化人心肌肌钙蛋白Ⅰ[J].检验医学,2007,22(3):304-307. 被引量:3
  • 3Knaak JB,Daly CC,Power F,et al.Physicochemical and biological data for the development of predictive organophosphorus pesticide QSARs and PBPK/PD models for human risk assessment [J]. Crit Rev Toxicol, 2004;34(2) : 143-207.
  • 4Costa LG,Cole TB, Furlong CE. Polymorphisms of paraoxonase (PONI) and their significance in clinical toxicology of organophosphates[ J]. J Toxicol Clin Toxicol, 2003,41 ( 1 ) : 37-45.
  • 5Miguel AS ,Eugenio V, Victoria C.Future applications of phosphotriesterases in the prophylaxis and treatment of organophosphorous insecticides and nerve agent poisonings [J]. Toxicol Lett,2004,151 ( 1 ) : 219-223.
  • 6Briseno-Roa L, Hill J, Notman S, et al. Analogues with fluorescent leaving groups for screening and selection of enzymes that efficiently hydrolyze organophosphorus nerve agents[J ]. J Med Chem, 2006,49 ( 1 ):246-255.
  • 7Gan KN, Smolen A, Eckerson HW, et al. Purification of human serum paraoxonase/arylesterase [J]. Drug Metabol Dispos, 1991,19 ( 1 ) : 100-106.
  • 8Furlong CE,Richter RJ,Chaptine C,et al. Purification of rabbit and human serum paraoxonase [J], Biochemistry, 1991,30(42): 10133 -10140.
  • 9Costa LG,Cole TB,Vitalone A,et al. Measurement of paraoxonase (PONI) status as a potential biomarker of susceptibility to organophosphate toxicity [J]. Clin Chim Acta,2005,352 (1-2) : 37-47.
  • 10Cole TB, Jampsa RL, Walter B J, et al. Expression of human paraoxonase ( PON 1 ) during development [ J ]. Pharmacogenetic s, 2003,13 (6) : 357-364.

共引文献5

同被引文献65

引证文献5

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部